Publication of insider information pursuant to Art. 17 MAR
Change of President and CEO at Carl Zeiss Meditec AG
Jena, Germany | May 7, 2025 | Carl Zeiss Meditec AG
The supervisory board of Carl Zeiss Meditec AG (ISIN: DE0005313704) in today’s meeting has agreed on a change in the Management Board of the company. Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG since January 1, 2022, will turn over his position to Maximilian Foerst, currently Head of ZEISS Greater China, on May 31, 2025. The handover is taking place at Dr. Weber’s own request and on best of terms with the Supervisory Board.
Maximilian Foerst joined Carl Zeiss AG in 1995 and, following initial roles in product management and marketing in the medical technology field, took over leadership of the Carl Zeiss sales and service companies in France and Korea and – since 2009 - ZEISS Greater China. Under his leadership, ZEISS achieved market leadership in the Refractive Laser business as well as a leading position in the intraocular lense business in China.
The region Greater China is the largest single market for Carl Zeiss Meditec AG with a revenue share of 26% in fiscal year 2023/24.
Along with his new role as President and CEO of Carl Zeiss Meditec AG, Maximilian Foerst has also been nominated as an Executive Board member of Carl Zeiss AG and will take over Dr. Weber’s responsibilities. Dr. Weber will leave the Executive Board of Carl Zeiss AG likewise on May 31, 2025.
In the view of the Supervisory Board of Carl Zeiss Meditec AG, management continuity is assured via the internal succession. The Chief Financial Officer, Justus Felix Wehmer remains in office. Leadership of the Strategic Business Units Ophthalmology and Microsurgery remains unchanged as well.

Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
Phone: +49 3641 220 116
investors.med@zeiss.com